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In July 2015 a multidisciplinary two-day workshop entitled “Musculoskeletal
Health in the 21st Century” was organised by the authors at the University
of Surrey. The aim of the workshop was to bring together some of the major
stakeholders including clinicians, basic scientists and funding bodies to focus
on current challenges in musculoskeletal health and discuss current
strategies for intervention and disease prevention. Workshop participants
discussed and debated the effects of physical activity, body condition, diet
and vitamins on the musculoskeletal system, focusing specifically on the
synovial joint. The workshop also included sessions on joint health, arthritis
prevention through physical activity (including biomechanics of
musculoskeletal tissues), effects of diet and nutrition, understanding the
underlying physiology and pathophysiology of cartilage and bone,
prognostic biomarkers and new insights from genetic diseases of the
musculoskeletal system. This Special Supplement of BMC Musculoskeletal
Disorders includes a general review article summarising some of the current
research in musculoskeletal health and includes abstracts presented at the
July 2015 workshop in Surrey.
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Recent epidemiologic and experimental data reinforced the concept that
diabetes mellitus (DM) is an independent risk factor for osteoarthritis (OA).
Besides a systemic inflammatory response that can affect joint tissues and
contribute to OA pathogenesis, direct effects of hyperglycaemia have been
shown to cause cell damage and induce inflammation by various
mechanisms in several tissues associated to diabetic complications.
Whether and how glucose directly affects joint tissues and cells is just
beginning to be unraveled. Indirect effects of high glucose can result from
enhanced formation of advanced glycation end products (AGEs) which
accumulate in OA cartilage in an age-dependent manner and play a pro-
inflammatory and pro-catabolic role mediated by activation of their
specific receptor, RAGE, on chondrocytes and synovial cells. Some direct
effects of high glucose have also been demonstrated, namely induction of
IGF-1 resistance [1] and inhibition of dehydroascorbate transport which
can compromise collagen synthesis [2]. Our studies have been aimed at
determining whether and how hyperglycemia affects chondrocyte
functions and contributes to OA development and progression. The results
obtained showed that high and low glucose concentrations regulate the
availability of facilitative glucose transporter (GLUT) isoforms and the
glucose transport capacity of human chondrocytes. High glucose
concentrations decrease the transport capacity and GLUT-1 protein
content without affecting its mRNA levels, but this ability to adjust glucose
transport capacity as a function of its availability is compromised in aged/
OA chondrocytes leading to its intracellular accumulation [3]. The
consequences of this are increased and prolonged ROS production [3] and
expression of metalloproteinases (MMP)-1 and -13 [4], IL-1b, TNF-a,
inducible nitric oxide (NO) synthase (iNOS) and NO production, mediated
by high glucose-induced NF-B activation [5], as well as decreased
responsiveness to TGF-b [4] and impaired autophagy [5]. High glucose is
thus sufficient to induce an inflammatory and catabolic response in human
OA chondrocytes. Furthermore, it potentiates pro-inflammatory effects of
IL-1b, namely IL-6, cyclooxygenase 2 (Cox)-2, prostaglandin E2 (PGE2) and
NO production [6]. The pro-inflammatory effects of high glucose in human
chondrocytes and diabetic mice, namely induction of Cox-2, IL-6 and MMP-
13 and production of PGE2, as well as decreased production of Collagen II,
have also been shown to involve impairment of anti-inflammatory
pathways, namely by decreasing PPAR-g expression [7].
Elucidating how high glucose modulates joint tissue homeostasis will
identify novel targets for development of innovative strategies both to
identify diagnostic and prognostic biomarkers of OA and to effectively
modify disease progression.
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OA is a disease affecting the metabolism of all joint tissues leading to
structural changes visible by imaging techniques. Unfortunately, features
visible by imaging are in most cases irreversible and progressively moving
towards worsening. One challenge for the next decade will be disease
detection at the early stage when the first molecular/metabolic changes
appear in joint tissues. Another challenge is to develop tools to assess the
efficacy of OA treatment on the natural history of the disease. Therefore,
there is an acute need for reliable biological markers that can facilitate
earlier diagnosis of OA, predict the progression of the disease and evaluate
the efficacy of therapeutic modalities.
A recent literature review resulted in the identification of 16 biochemical
markers investigating cartilage matrix turnover. Nine concerned collagen
type II degradation (Coll2-1, Coll2-1NO2, CTX-II, Helix-II, C2C, TIINE, CIIM) and
synthesis (PIIANP, PIICP). Keratan sulphate, chondroitin sulphate 846 (CS846)
and ARGS-aggrecan fragment investigate proteoglycans degradation. Serum
cartilage oligomeric matrix protein (COMP), deamidated-COMP (D-COMP),
fibuline-3 fragments (Fib3-1 and Fib3-2) were the other biochemical markers
that are considered as markers of cartilage matrix metabolism.
Risedronate and strontium ranelate, two drugs currently used to treat
osteoporosis decreased urinary CTX-II levels suggesting that they can
modulate cartilage metabolism, even if they did not alter radiological
progression. However, recently, it was demonstrated that CTX-II was more
strongly associated with bone markers (i.e. uNTXI, uCTXI, serum PINP, and
osteocalcin) than with other cartilage markers (PIIANP, sCS846, sCOMP),
while the “other” cartilage markers were not so strongly associated with
the bone markers. These data indicate that CTX-II might reflect bone
rather than cartilage metabolism. In an exploratory study investigating
the effects of three intra-articular injections of hyaluronic acid (Hylan GF-
20) on the evolution of 10 biochemical markers, we have demonstrated
that uCTXII, sColl2-1 and sColl2-1NO2 levels were significantly affected by
treatment suggesting that these markers are sensitive to metabolic
change occurring in one single joint. More recently, we have observed
that three months treatment with bio-optimized curcumin significantly
decreased sColl2-1 level in 24 patients with knee OA, suggesting that
sColl2-1 could be a companion marker to assess curcumin efficacy at an
individual level and in the next phases of its clinical development.
Although many OA-related biomarkers are currently available they exist in
various states of qualification and validation. At this time, none of the
existing biomarker can be considered as a surrogate marker of clinical
and imaging feature for the diagnosis or prognosis of the disease. In this
context, the recent development of large cohort designed to qualify
biomarker will accelerate biochemical marker implementation in clinical
research.
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Over the past century, global health priorities were largely focused on
communicable diseases. With the world’s population growth, increased
average age and decreased death rates, people are now living longer and
becoming increasingly susceptible to the non-communicable diseases,
including musculoskeletal (MSK) disorders. The recent Global Burden of
Disease (GBD) Study estimated the burden disability in 187 countries and
21 regions of the world for the years 1990, 2010 and 2013 of all MSK
disorders - osteoarthritis (OA), rheumatoid arthritis (RA), gout, low back
pain (LBP), neck pain (NP) and all other musculoskeletal disorders.
Throughout the world, the prevalence and burden from MSK conditions
were exceptionally high. All MSK disorders combined caused 21.3% of the
total years lived with disability (YLDs) globally - second to mental and
behavioural problems (23.2%). When taking into account both death and
disability, all MSK disorders combined accounted for 6.7% of the total
global disability-adjusted life years (DALYs), which was the fourth greatest
burden on the health of the world’s population (third in the developed
countries). Out of the 291 conditions studied, LBP ranked first (highest)
for the disability (YLDs), and sixth for the overall burden (DALYs). For NP,
the condition ranked fourth highest for YLDs, and 21st for DALYs. ‘Other
MSK disorders’ ranked sixth highest for YLDs and 23rd for DALYs.
Osteoarthritis, RA and gout were also significant contributors to the
global disability burden. In addition to this burden of disability as
estimated by these summary measures of health, there is the impact on
the individual’s quality of life and economic independence as well as the
costs to society due to health and social care and due to work loss.
Despite this enormous and growing burden there is a lack of priority and
of policies focusing on musculoskeletal health. This needs to change if
we are to meet the demands of an ageing population that needs to be
able to remain economically independent.
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The Sofat laboratory currently investigates the mechanisms responsible for
pain and tissue damage in arthritis. Clinical studies include ‘Pain
management in osteoarthritis using centrally acting analgesics’ (http://
public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12175) funded by the
Rosetrees Trust. This clinical trial is testing whether drugs that inhibit pain
processing pathways in the brain can help with pain in the hand caused by
osteoarthritis. Other clinical studies include the ‘Pain Perception in
Osteoarthritis’, or PAPO study, investigating tissue damage and pain in
people undergoing knee replacement surgery for osteoarthritis. Both studies
are on the UK NIHR portfolio of network-adopted studies.
Our laboratory has a translational approach, with techniques including
magnetic resonance imaging (MRI) to decipher regions of damage in
affected joints and evaluating which brain regions are activated by arthritis
pain. We also use non-invasive quantitative sensory testing (QST) methods
to identify pain pathways. QST identifies sensation and pain thresholds by
stimulating the skin.
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Our laboratory research uses a basic science mechanistic approach to
investigate the influence of endogenous damage-associated molecular
patterns (DAMPs) in driving chronic inflammation in joints. Molecules of
interest include interaction of the DAMPs tenascin-C and fibronectin with
oral pathogens.
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Femoral acetabular impingement (FAI) is thought to be a key underlying
reason for the development of osteoarthritis of the hip. There are two
main types of FAI, cam-type and pincer-type. The cam-type FAI gives rise
to cartilage delamination initially thought to occur on the acetabular side
of the joint. The purpose of the current study was to look at the effects of
cam-type impingement on the generation of shear strains at the bone/
cartilage interface, using both experimental and finite element simulation
methods. Sagittal slices (n=9) of femoral porcine cartilage-bone, 10 mm
thick, were loaded using a five-axis custom test machine with a curved
(radius 90 mm) steel indenter. The five-axis test machine allowed the
samples to be subjected to compression and mixed compression/shear
loading regimens. The specimen strains were measured using two
dimensional digital image correlation (DIC). Each test was also simulated
using finite element analysis, and the results compared with the DIC data.
The specimens were then cyclically loaded either with or without damage
to the cartilage layers; damage simulated clinically reported lesions.
Maximal shear strain was found at the cartilage-bone interface, and was a
function of compressive loading level. The finite element predictions
matched the DIC measurements. The two parameters that were most
important in terms of shear strain were the cartilage thickness and contact
area radius. It was found that increased cartilage thickness and increased
contact radius gave rise to higher shear strains. Cyclically loading the
damaged specimens produced features of cartilage delamination
consistent with clinical observations. The results of this study indicate high
shear strain at the bone/cartilage interface is a possible mechanism
leading to cartilage delamination, and may be the mechanism behind
cartilage degradation in patients with cam-type FAI.
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In human medicine musculoskeletal diseases rank (together with mental
disorders) first in reasons for occupational disability and have a huge impact
on both quality of life and overall healthcare costs [1]. The current increase
in life expectancy, together with decreasing societal acceptance of impaired
mobility, have strongly pushed musculoskeletal research in recent years.
The classic animal models for research into musculoskeletal disease are small
rodents, especially mice and rats. As larger species, goats and to a lesser
extent sheep have been the species of choice. This choice was largely based
on practical and logistical considerations such as the required size,
availability, costs and ease of handling, rather than on biomedical criteria.
fThe growing acceptance of the “One Health, One Medicine” concept has,
together with better knowledge of fundamental differences between
mammalian species in articular cartilage biology and the increasing pressure
to reduce, refine and replace (the three “Rs”) animal experimentation, led to
a change in attitude towards the use of animal models in musculoskeletal
research [2]. Whereas small rodents may still be a logical step after in vitro
research, the fundamental differences between articular cartilage
composition of smaller species and those heavier than about 1Kg [3],
together with the increasing recognition of the role of biomechanics within
the joint, cast severe doubts on the validity of these species for anything but
very basic work in musculoskeletal research. In contrast, within the “One
Medicine” concept it is clear that in veterinary medicine there are several
species featuring a high prevalence of musculoskeletal disorders that are
very similar to those seen in humans. This applies to dogs with
intervertebral disc disease [4] and chronic joint disorders (especially
osteoarthritis (OA)) in both horses and dogs [4]. These developments have
led to a gradual shift in the use of animals in musculoskeletal research. Also,
regulatory bodies are making this shift of mind with the US Food and Drug
Administration (FDA) now requiring preparatory work in horses before
approval for certain orthopaedic devices is granted.
There is one other important aspect to this development. Whereas the
classic animal models were solely used to the benefit of human research,
research in dogs and horses will forcibly lead to medical improvements
for these species, as they are patients too and hence not only
experimental animals, but target species as well. This is an important
asset for the ethical justification for the use of animals for scientific
research.
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Osteoarthritis (OA) is the fastest growing cause of disability worldwide [1].
In the absence of effective therapies, patients may wish to take some
control of their own condition by making dietary changes that have the
potential to ameliorate symptoms or reduce disease progression.
A number of dietary factors have been associated with OA symptoms or
progression. Most notably, in those overweight, weight reduction of
≥10% has the potential to lead to important changes in pain and
function [2]. Losing weight also reduces pain-associated inflammation [3].
Weight loss combined with physical activity has an even greater capacity
to improve pain and function [4].
It has been suggested that OA is a metabolic disease in which lipids
essentially contribute to the pathophysiology of cartilage degradation [5].
Dietary long-chain ω-3 PUFA may affect articular cartilage composition and
appear to have beneficial effects in OA [5]. In a US cohort of individuals
with, or at high risk of, knee OA, there was a significant inverse
relationship between total n-3 PUFAs and patella-femoral cartilage loss [6].
A positive association has been shown between elevated serum
cholesterol and OA; hypercholesterolemia (OR 1.61; 95% CI 1.06-2.47) and
high serum cholesterol (3rd vs. 1st tertile: OR 1.73; 95% CI 1.02-2.92) were
independently associated with generalized OA in the Ulm study [7].
Hence there may be a potential benefit in adopting dietary cholesterol-
lowering strategies (such as consumption of sterol/stanol spreads/drinks).
Vitamin D affects the state of multiple articular structures. The evidence
for association between the vitamin D biomarker, serum 25(OH)D, and
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OA was assessed in a systematic review. For knee radiographic OA
progression and cartilage loss, there was strong evidence for an
association with low 25(OH)D [8].
Vitamin K is important in cartilage metabolism as an inhibitor of
extracellular matrix calcification and a promoter of cell survival/
proliferation. In the US MOST study, vitamin K deficiency was associated
with incident radiographic knee OA and MRI-based cartilage lesions (RR
2.39; 95% CI, 1.05-5.40) compared with no deficiency [9].
Hence, dietary recommendations are the following:
▪ lose weight, if overweight, preferably combined with exercise;
▪ reduce plasma cholesterol by dietary means;
▪ at least for a trial period, increase intake of long-chain n-3 fatty acids
preferably by eating oily fish twice a week;
▪ aim for a safe level of sun exposure, eat rich vitamin-D dietary sources
or take vitamin D supplements, ≤ 25 µg/d;
▪ increase vitamin K intake by eating green leafy vegetables.
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Self-management (SM) programs for people with arthritis or other chronic
diseases are commonplace and usually delivered by lay leaders. There is
evidence indicating these programs are effective, although systematic
reviews show these improvements are small.
The self-management program for Osteoarthritis of the Knee (OAK) differs
from other programs in a number of aspects. It is disease-specific and
tailored for people with OAK. It was developed using an ENAT survey, a
collaborative approach, and a Plan Do Study Act (PDSA) model. It was
planned purposely for implementation in hospitals or community
settings. The program is detailed for delivery by health professionals. In
particular, exercise and disease coping strategies are promoted within a
SM construct to improve quality of life and general health as well as
reducing pain.
The program was tested using an uncontrolled quality assurance study
and the results were positive in pain, quality of life and physical function.
A randomised controlled trial (RCT) was undertaken, where, the OAK
group showed statistically significant improvements when compared with
the control group with regard to pain, quality of life and function on the
basis of WOMAC and SF-36 measurements taken 8 weeks and 6 months
from baseline.
The OAK program is conducted in a group setting over six weekly sessions
of 2.5 hours. This allows participants to progress over time by incorporating
and consolidating new information learned each week. In addition to the
weekly sessions, handouts and reference book readings are given.
For optimum group dynamics, the program is delivered by the same two
health professionals to a group of 12-14 participants. The fidelity of the
OAK program is maintained by the use of a scripted facilitators’ manual.
Using a holistic approach, the program addresses multiple aspects of care:
osteoarthritis (explanation and implications), SM skills (goal-setting, problem-
solving, positive thinking and improving self-efficacy), medications (types,
interactions and current trends), pain management strategies (cognitive and
pharmacologic), fitness and exercise (strength, flexibility, aerobic), joint
protection, nutrition and weight control, falls prevention (balance and
proprioception), environmental risks, and coping skills.
The OAK program has been sustained by development of health
professional training workshops. OAK programs are delivered throughout
Australia primarily by physiotherapists especially those working in district
hospitals or primary care settings. To reduce costs, we have recently
trialled programs using self-management trained peer leaders and health
professionals which has worked extremely well.
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We are an ageing society, with falling birth rates and increasing life
expectancy. However healthy life span is not keeping pace and on average
older adults can expect to be unwell for the last decade of life. Many
factors influence both lifespan and healthspan but in humans one of the
key factors is likely to be increasing physical inactivity. To separate out
those elements of the ageing phenotype that are due to inactivity from
those which are intrinsic to the ageing process, we recruited 125 adults
aged 55-79 who had maintained a high level of physical activity through
their adult lives. We compared these with age matched healthy older
adults who were not involved in regular physical activity and healthy
young subjects. The subjects were assessed for key features known to
change with ageing including sarcopenia, reduced bone mineral density,
adiposity, cardiovascular and lung function as well as markers of immune
ageing. We have already reported the physiological data which revealed
that many features of ageing including lean body mass, adiposity and
muscle strength did not change with age in the physical active group,
though other effects were seen such as a decline in lung capacity (FEV1)
and maximal heart rate. Here we report that a comparison of immune
phenotype in the exercising and non-exercising groups showed that
thymic output was significantly reduced in the inactive group compared to
both the young subjects (p<0.002) or the physically active older subjects
(p<0.009). The numbers of naïve T cells was also maintained in the active
elders, though the rise in the numbers of senescent T cells was not
protected by an active lifestyle. We conclude that an active lifestyle
through adulthood can prevent many of the physiological and immune
features normally attributed to ageing.
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Non-invasive techniques for studying macrophages in joint
inflammation
Harrie Weinans
UMC Utrecht, The Netherlands
BMC Musculoskeletal Disorders 2015, 16(Suppl 1):S10
Folate-based radiotracers have been used in patients with cancer and
inflammatory diseases to visualize folate receptor expressing cells using PET
or SPECT techniques. Activated macrophages express folate receptor beta
(FR-b) and this allows specific imaging of these cells in-vivo. From previous
work using SPECT imaging to visualize folate receptor expressing
macrophages in both animal models and in patients with OA we know that
macrophages are present in OA affected joints. However, it remains unclear
what role these macrophages play in the different stages of OA and
whether their role can be influenced by specific targeting.
In Wistar rats osteoarthritis was induced using a low dose of intra-articular
papain injections in one knee joint combined with exposure to a moderate
exercise protocol. After six weeks and twelve an in vivo folate SPECT/CT
scan and micro-CT analyses were performed. Macrophages from human
peripheral blood monocytes were cultured (7 days) in the presence of GM-
CSF (M1 proinflammatory phenotype) or M-CSF (M2 anti-inflammatory
phenotype). Subsequently the macrophages were treated with LPS,
cytokines (IL-4, IL-10, IFN-y) or a corticoid steroid (triamcinolone acetonide,
1µg/ml). Folate receptor beta (FRb) as well as other macrophage marker
expressions were measured using FACS.
Intra-articular injections with triamcinolone strongly enhanced FRb+
macrophage activation and fully prevented osteophyte formation. There
were no beneficial effects of the corticoid steroid against cartilage
degradation or subchondral bone sclerosis. In in-vitro cultures triamcinolone
strongly induced the monocyte-macrophages differentiation towards CD163
+ and FRb+ cells, specifically in GM-CSF stimulated (M1) cultures. Addition of
triamcinolone to M-CSF stimulated (M2) monocytes showed enhanced IL10
expression on mRNA level.
In conclusion triamcinolone enhanced FRb expression in monocytes that
were induced to macrophage differentiation. The triamcinolone injections
stimulate synovial macrophage activation and triggers the macrophages
towards a more anti-inflammatory subtype.
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Canine chondrodystrophic intervertebral disc disease (Hansen type I
disc disease)
Clare Rusbridge1,2
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Intervertebral disc disease (IVDD) is the most common spinal disease in
dogs. Chondrodystrophic dogs, which have disproportionably short and
curved limbs, are predisposed to Hansen type I IVDD and of these the
miniature Dachshund is over represented [1,2], is more likely to be
presented at an earlier age [3] and is at greater risk of a severe spinal
cord injury [4]. The tendency for IVDD in Dachshunds is inherited [5,6]
and a major locus on chromosome 12 harbours genetic variations
affecting the development of intervertebral disc calcification [7]. Hansen
type I disc degeneration is thought to occur because of loss of
notochordal cells which produce proteoglycans which “hold water” in the
disc. Chondrodystrophic dogs have a primary deficiency of notochordal
cells, a study found that large notochordal cells in the nucleus pulposus
of chondrodystrophoid dogs formed 13% of the cell population in young
dogs and fell to 0.4% in adults, whereas they were the predominant cell
type in the nonchondrodystrophoid dogs at all ages [8]. Thus
chondrodystrophoid dogs suffer early degenerative changes in the disc
and a concomitant reduction in proteoglycan content, increased collagen,
and loss of water content making the discs likely to herniate [8]. Certain
lifestyle factors may increase or decrease risk of IVDD and this is currently
under investigation. There is a suggestion that exercise (including stair
climbing) reduces the incidence of disc calcification [9]. By contrast it has
been hypothesized that obesity/lack of postural muscle strength may
increase risk. Dachshunds with intervertebral disc extrusion had
significantly smaller cross sectional area and greater fat infiltration in the
epaxial muscles (muscles which lie dorsal to the horizontal septum of the
vertebrae which mobilize and globally stabilize the trunk [10]) compared
to dogs presenting with fibrocartilagenous embolism (another acute
onset intervertebral disc related spinal disease) [11]. In addition
chondrodystrophic dogs may have increased risk of IVVD if they have a
more extreme conformation e.g. Dachshunds that have a longer back
and shorter limbs are more at risk [12] and breeds with a comparatively
Figure 1(abstract S10) Macrophage activation determined after injection of 111In-DTPA-folate using SPECT/CT in Papain induced osteoarthritis (OA)
combined with moderate exercise. Representative sagittal SPECT/CT images of knee joints from representative animals per experimental group. CT
images shown in black and white were used for anatomical reference, the SPECT images are shown in colour. Patellar bone is shown with osteophyte
formation highlighted in red
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heavy head such as the Bassett Hound may be more at risk of cervical disc
disease. Breeds with a tendency for kyphoscoliosis such as the French
Bulldog may be more at risk of IVDD in the IVDs adjacent to a vertebral
malformation [13,14]. This presentation details the pathogeneis, clinical
presentation, diagnosis and treatment of IVDD in chondrodystrophic dogs.
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research: academia, industry, health services, and patients
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The main activity of Orthopaedic Research UK (ORUK) is to provide funding
to centres of excellence to conduct research in the field of orthopaedics, in
order to benefit patients suffering from bone and joint disorders. However,
the majority of the grants awarded will not make it to the market as
products, surgical techniques or novel rehabilitation approaches.
Therefore, in general, grants are made with no expectation of a financial
return and very often with no measureable patient benefit. But in the
event when the researchers manage to generate intellectual property (IP)
and a commercial opportunity, it is expected that the funder should also
share the financial benefits in order to reinvest the money back into its
pursuit of its mission.
Since 2004, ORUK has invested over £8.2m on 120 projects in 37 institutions,
which has thus far generated nil return on investment. Even though so far
ORUK has managed to file three patents – in 2009, 2013 and 2014 - the
organisation has yet to see the long-term benefits for the stakeholders.
ORUK is addressing a perceived lack of efficiency to show impact on
patients by implementing a new approach through a specific translation
research funding (TRF) programme within its strategy. ORUK is aiming to
promote the innovation process to ensure that the money invested in
research is given the best opportunity to translate into meaningful
outcomes.
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Musculoskeletal health and osteoarthritis in the UK army – the
ADVANCE study (Armed Services Trauma Rehabilitation Outcome
Study)
Alexander Bennett
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Trauma is a well recognised risk factor for the future development of
osteoarthritis (OA). The Armed Services Trauma and Rehabilitation
outcome study (The ADVANCE study) is a 20 year cohort study
comparing medical and psychosocial outcomes of military personnel both
exposed and not exposed, to significant trauma.
The Bio-Mil-OA study, a sub-study of the ADVANCE study, is an ideal
opportunity to investigate the predictive value of biomarkers in joint pain
and osteoarthritis.
The ADVANCE study is a 20 year cohort study of 600 combat casualties
and 600 matched non exposed participants investigating the predictive
value of biomarkers and trauma on the long term development of pain
and OA in the hip and knee. Validated serum biomarkers for OA, knee
and hip radiographs and patient reported outcomes for pain and
function will be taken at baseline and at 5 years.
The predictive value of the biomarkers in predicting OA development and
progression and joint pain in those exposed to different levels of trauma
will be investigated using quantitative immunoassays for catabolic
markers of cartilage matrix degradation.
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Exercise encompasses physical activity (habitual, sporting), and exercise
programmes to improve and maintain joint heath. Clinical guidelines
recommend exercise for osteoarthritis (OA) e.g. NICE, EULAR, OARSI.
Benefits of moderate exercise include weight control (obesity is a known
risk factor for OA) and joint health (beneficial for cartilage). Specific
exercises aim to achieve optimal biomechanics to protect joints (joint
alignment, load reducing strategies) and improve muscle strength,
endurance, power, flexibility and co-ordination. Other physiotherapy
principles include sport/task specific exercises, personalised medicine
(exercises tailored for the individual) and neuromuscular control of
movement (screening and retraining using specific exercises). Manual
therapy techniques (pain management, mobilisations, muscle stretching)
can improve exercise outcomes. Effects of exercise on pain and function
are comparable with those for non-steroidal anti-inflammatory drugs.
Exercise forms part of biopsychosocial management, using tailored, patient
centred interventions based on assessment, with shared decision making.
Three levels of prevention include: primary (preventing injury and onset
of OA), secondary (preventing progression of OA) and tertiary (managing
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complicated, long-term health problems). The Arthritis Research UK
Centre for Sport, Exercise and Osteoarthritis is focussing on secondary
prevention of progression of injury and/or overuse to OA. Biomechanical
and neurophysiological mechanisms of abnormal movement and joint
loading are investigated using 3D motion analysis and electromyographic
techniques, and evidence is emerging that mechanistic-based exercises
can correct abnormal movement.
Movement screening tools in clinical/field environments are used increasingly
to assess movement control and functional performance, primarily in sport,
to predict injury and/or inform intervention. Robustness of screening tools is
variable, in terms of reliability, validity and prediction of injury risk. Consensus
is needed for terminology and establishing which screening tests are
appropriate for specific cohorts and movement problems.
High quality longitudinal trails are needed to ensure effective use of exercise
for OA prevention. Activity needs to be maintained for long-lasting effects
but adherence to changing lifestyle remains a major challenge. For exercises
targeting movement problems, studies need to elucidate which elements,
modes, doses, and frequency and duration of exercise are optimal for
specific joints and body regions.
It remains unknown whether exercise can influence disease parthenogenesis
and progression. Evidence of cost-effectiveness of exercise as a clinical
intervention for OA is also needed. Understanding and overcoming barriers
to exercise and enabling access will be crucial for widespread uptake of
exercise. Translation research is needed to determine how to change
practice and influence GP referral to exercise programmes.
S15
Surgeon General’s bone health project: translation of research to
mitigate injury risk in Royal Marines recruits
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Overuse injury, including stress fracture (SF), in military training results in
significant economic losses and individual discomfort. The 32-week Royal
Marine (RM) training programme is recognised worldwide as the most
arduous initial training programme. Research has failed to fully identify bone
density and structural differences between SF personnel and controls due to
inadequate adjustment for confounding factors and poor sample size.
Moreover, whilst associations have been reported between serum 25-
hydroxyvitamin-D (25(OH)D) and SF risk, the threshold for this effect remains
unclear. This programme determined if 25(OH)D concentrations were
associated with SF risk during military training, and investigated physical
and bone differences between matched (age, body size and aerobic fitness)
injured and uninjured recruits, to inform future policy and practice.
RM recruits (n=1090; males aged 16-32 y) were followed through training,
where 78 recruits (7.2%) suffered 92 SF in total. Anthropometric measures
and aerobic fitness were assessed at week-1. Lumbar spine (LS), femoral
neck (FN) and whole body (WB) Bone mineral density (BMD) (Dual X-ray
Absorptiometry), and tibial bone parameters (peripheral Quantitative
Computer Tomography), were measured in matched (injured vs. uninjured)
pairs. Venous blood samples drawn at weeks 1, 15 and 32, were analysed
for serum C-terminal peptide concentration (as a marker of bone
resorption), 25(OH)D and PTH.
Age (<18 y; >27 y), body mass (<65 kg) and fitness were associated with
injury risk (P<0.05). Recruits with a baseline 25(OH)D concentration <50 nmol.
L-1 had a higher SF incidence than recruits with 25(OH)D concentration >50
nmol.L-1 (c2(1)=3.564, p=0.042; odds ratio 1.6 (95% CI 1.0-2.6)). There were
weak inverse correlations between week-15 25(OH)D and PTH concentrations
(r=-0.209, p<0.001) and week-32 (r=-0.214, p<0.001), but not at baseline. BMD
at the LS, WB and FN were lower in SF compared with uninjured recruits
(ANCOVA, P<0.001). Structural differences between SF and uninjured recruits
were evident in all slices of the tibia, but most prominently at the 38% slice.
There was a negative correlation between bone cross-sectional area and
BMD at the 38% tibial slice. There was no difference in CTx concentration
between SF and uninjured recruits at any stage of training.
Thus, differences in anthropometric, aerobic fitness, baseline serum 25
(OH)D concentration, bone mass and bone structure, between SF and
uninjured recruits, provided evidence to inform changes in RM physical
selection standards to reduce injury. Further work examining the effects
of vitamin D supplementation on SF risk has been initiated to support
recruit health and wellbeing.
S16
Vitamin D and bone health
Susan Lanham-New
Department of Nutritional Sciences, Faculty of Health and Medical Sciences,
University of Surrey, Guildford, GU2 7XH, UK
BMC Musculoskeletal Disorders 2015, 16(Suppl 1):S16
Throughout the life-cycle, the skeleton requires optimum development and
maintenance of its integrity to prevent fracture. Bones break because the
loads placed upon them exceed the ability of the bone to absorb the energy
involved. It is now estimated that 1:3 women and 1:12 men over the age of
55 years will suffer from osteoporosis in their lifetime and in the UK, at a cost
in excess of £1.7 billion per annum to the exchequer. The pathogenesis of
osteoporosis is multi-factorial. Both the development of peak bone mass and
the rate of bone loss are determined by key endogenous and exogenous
factors. Calcium supplements appear to be effective in reducing bone loss in
late menopausal women (>5 years post-menopause), particularly in those
with low habitual calcium intake (< 400mg/d). In younger postmenopausal
women, who are not vitamin D deficient, vitamin D supplementation has
little effect on BMD. However, vitamin D and calcium supplementation
studies have been shown to reduce fracture rates in the institutionalized
elderly but there remains controversy as to whether supplementation is
effective in reducing fracture in free-living populations. Re-defining vitamin
D requirements in the UK is urgently needed since there is evidence of
extensive hypovitaminosis D in the UK. Low vitamin D status is associated
with an increased risk of falling and a variety of other health outcomes and is
an area that requires urgent attention. The role of other micronutrients on
bone remains to be fully defined, although there are promising data in the
literature for a clear link between vitamin K nutrition, dietary protein and
dietary alkali on skeletal integrity including fracture reduction.
S17
What can we learn about joint degeneration from rare and orphan
diseases?
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William Harvey, the great English physician of the 17th century, observed
“Nature is nowhere accustomed more openly to display her secret mysteries
than in cases where she shows tracings of her workings apart from the beaten
paths; nor is there any better way to advance the proper practice of medicine
than to give our minds to the discovery of the usual law of nature, by careful
investigation of cases of rarer forms of disease” [1]. The history of medical
science has proven Harvey correct; studying severe phenotypes of rare
diseases has helped elucidate pathophysiological mechanisms of more
common disorders and led to the identification of new biomarkers and
therapeutic targets [2]. For example the development of bisphosphonates,
the most successful class of bone active agent, owes a debt to research on
hypophosphatasia. More recent research on rare bone syndromes has
helped identify new targets to inhibit bone resorption and stimulate bone
formation including cathepsin K and sclerostin. Drugs against both these
targets are now in clinical trials. Osteoarthritis (OA) is a major cause of
morbidity and disability. It is also the only major musculoskeletal disorder
for which there are no effective therapies, other than pain relief and
eventual joint replacement. Recent studies on rare cartilage syndromes have
identified some potential therapeutic target including GDF5 and lubricin.
Research from our laboratory has focussed on the early onset, aggressive joint
destruction which occurs in the osteoarthropathy of the rare disease
alkaptonuria (AKU). AKU is a single gene defect in tyrosine metabolism, which
is characterised by ochronosis, the deposition of pigmented polymers in
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connective tissues particularly cartilage. Studying tissue samples from
AKU patients and from AKU mouse models has revealed significant
parallels with the pathophysiology of OA. We have discovered several
previously unidentified microanatomical changes in AKU joints which
were subsequently recognised in joint degeneration associated with OA
and ageing. Of these the most significant are high density mineralised
protrusions (HDMPs). These novel micoanatomical structures arise via the
extrusion of a mineralisable matrix through cracks in the subchondral
plate. Formation of HDMPS constitutes a previously unrecognised
mechanism of joint destruction [3].
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Rare skeletal diseases are a diverse group of diseases that primarily affect
development of the skeleton. There are more than 450 unique phenotypes
that, although individually rare, have an overall prevalence of at least 1 per
4,000 children. Pseudoachondroplasia (PSACH) and multiple epiphyseal
dysplasia (MED) are skeletal diseases caused by missense mutations/
deletions in the genes encoding important cartilage extracellular matrix
proteins (ECM), and are characterized by disproportionate short stature, joint
pain and early-onset osteoarthritis.
In-depth characterization of MED and PSACH mouse models has revealed
that endoplasmic reticulum (ER) stress, reduced cell proliferation and
abnormal ECM assembly are important pathological consequences of
mutant protein expression. Ongoing work aims to consolidate data from
other models of skeletal disorders using a systems biology approach as part
of the EU FP7 SYBIL (Systems biology for the functional validation of genetic
determinants of skeletal diseases) project, in order to gain a mechanistic
understanding of disease processes and to deliver new and validated
therapeutic targets.
Key to delivery of new targets and therapies is the identification of
relevant disease biomarkers, which will allow the monitoring of responses
to therapeutic interventions. This is particularly critical for skeletal
diseases, for which biopsy material is not readily accessible. We have
identified differences in the extractability of a number of ECM
components from the cartilage of MED and PSACH mouse models,
relative to controls. The differences in extractability of these proteins
(which include FACIT collagens (types XII and XIV), tenascins (C and X),
and fetuin A) may represent differences in the stability of these proteins
within the cartilage ECM, which might potentially be exploited for use as
biomarkers of disease progression. We are currently using biochemical
and mass spectrometry analysis of easily obtained biological samples
such as blood, urine and cell culture medium in order to identify and
validate novel biomarkers for skeletal diseases.
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Low back pain (LBP) is one of the most common musculoskeletal disorders,
with an estimated 84% of the population experiencing LBP at some point in
their lifetime. As with most musculoskeletal disorders, the prevalence of LBP
increases with age, suggesting incidences of LBP are likely to increase in the
future due to a global aging population, changes in lifestyle and
occupational stresses. Although the causes of LBP are multifactorial,
increasing evidence implicates intervertebral disc (IVD) degeneration as a
major contributor, with loss of IVD integrity leading to the destabilization of
the spinal motion segment, resulting in pain and disability.
The IVD is a complex structure that allows movement between adjacent
vertebrae and sustains the load applied through the spine. It consists of the
peripheral annulus fibrosus (AF), a ligamentous lamellar structure composed
predominantly of type I collagen fibres, and the central nucleus pulposus
(NP), a highly hydrated structure, composed of the proteoglycan aggrecan,
interspersed with type II collagen fibres. Only 1% of the IVD volume is
occupied by its constituent cells, but they assume a key role, as they
maintain IVD homeostasis. In degeneration there is an alteration in NP cell
biology leading to diminished cell numbers and altered cell function
resulting in an imbalance between matrix synthesis and degradation,
particularly within the NP.
Current medical treatments for IVD degeneration rely on conservative
therapies (e.g. pain relief, exercise therapy) and, when these fail, surgery.
Surgical treatments such as spinal fusion and disc replacement have shown
satisfactory results in alleviating pain, but are not devoid of complications
and long-term clinical outcomes still remain poor. Thus, there is an urgent
need for alternative therapies focussed on correcting the underlying
pathogenesis and aberrant cell biology of IVD degeneration. As such many
researchers, including ourselves, are focussing on the development of novel
cell-based therapies. However, in order for these to be successful an
appropriate cell source for implantation and tissue regeneration must be
identified.
In this presentation we discussed the pathophysiology of IVD degeneration,
efforts to elucidate the phenotype of human IVD cells and how this has
allowed development of mesenchymal stem cell (MSC)-based therapies for
IVD regeneration. In particular it focused on our efforts to identify the
optimal MSC source and growth factor to direct differentiation and enhance
tissue formation, as well as the influence microenvironment has on
regeneration strategies.
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Development of biocompatible materials has great potential in biomedical
engineering both for in vitro studies as well as for in vivo applications. Two-
and three-dimensional carbon nanotube (CNT) substrates imitating and
providing an extracellular matrix-like structure are promising constructs as
cell-supporting scaffolds. Lately, they have received considerable interest
in tissue engineering; however, cellular responses to nanoscale stimuli
need to be better understood.
Here, we present the preliminary results on the effect of CNT-based
scaffolds on the proliferation and arrangement of primary canine
chondrocytes (PCCs). We aim to develop scaffolding materials for the in
vitro cultivation of normal and neoplastic cells with the ultimate objective
of using them for applications such as tissue implants in cartilage repair
and tissue regeneration after surgical intervention.
In the proposed studies we aim to use an aerogel network of CNTs that
has been drawn from a vertically aligned array as a synthetic substrate
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for the growth and alignment of primary canine chondrocytes. This
aerogel consists of CNTs that are aligned parallel to the major axis of the
CNTs; they have exceptionally low densities, are electrically and thermally
conductive whilst maintaining very high tensile strength and elasticity.
We are studying the cell growth, adhesion, morphology, viability and
metabolism of cells seeded onto CNT substrates.
Preliminary results to date have revealed that PCCs are capable of
proliferating on CNT-based scaffolds, although the cell viability seems to
be slightly decreased in comparison to the conventional 2D cell culture.
Moreover, our nanosubstrates are able to induce directional cell growth
of PCCs via aligning cells along CNTs. The latter is essential for in vivo
application of nanosubstrates in tissue regeneration.
Cite abstracts in this supplement using the relevant abstract number,
e.g.: Matta-Domjan et al.: Carbon nanotubes: a promising tissue
engineering approach for in vitro cultivation & differentiation of primary
canine articular chondrocytes. BMC Musculoskeletal Disorders 2015, 16
(Suppl 1):S20
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